(2003). Substrate specificity of CDK2-cyclin A. What is optimal? J. Biol. Chem. 278, 50956-50960.Stevenson-Lindert LM, Fowler P, Lew J: Substrate specificity of CDK2-cyclin A. What is optimal? J Biol Chem 2003,
图1. HHT破坏了CDK2/Cyclin A之间的PPI a. Cavityplus软件对CDK2/Cyclin A复合物可成药结构域的预测;b. LIVS (LIgand Virtual screening) pipeline对FDA批准的1952个小分子药物进行虚拟筛选;c. CDK2与HHT互作的分子模拟。 作者进一...
CDK2/CYCLIN A激酶的磷酸化目标序列为HHASPRK。基于磷酸化多肽具有抗氨基肽酶切离的功能，通过荧光共振能量转移法（Fluorescence resonance energy transfer；FRET），即传递激发状态的能量由处于较短波长的供体（donor）到覆盖供体波长的受体（acceptor），使得距离依赖性反应的供体的散发光子淬灭（quench），使用2个荧光...
2, James N. Blaza 3, Jane A. Endicott 1*, Martin E. M. Noble 1 & Marco Salamina 1,5* p27KIP1 (cyclin-dependent kinase inhibitor 1B, p27) is a member of the CIP/KIP family of CDK (cyclin dependent kinase) regulators that inhibit cell cycle CDKs....
CDK2 CYCLIN A,产品货号|编号:Invitrogen-PV3267,价格及说明书详询!Invitrogen/life technologies(Gibco,Biosource,MP bio,Zymed,Caltag,Dynal) CDK2 CYCLIN A 的详细介绍 CDK2 CYCLIN A,产品货号|编号:Invitrogen-PV3267,价格及说明书详询!Invitrogen/life technologies(Gibco,Biosource,MP bio,Zymed,Caltag,Dynal...
Cyclin-dependent kinase 2 (CDK2) complex is significantly over-activated in many cancers. While it makes CDK2 an attractive target for cancer therapy, most inhibitors against CDK2 are ATP competitors that are either nonspecific or highly toxic, and typic
We have used siRNA to knockdown cyclin A2, the major cyclin A isoform in somatic cells, and cdk2 inhibitors to examine the role of the G2 phase cyclin A/cdk2 complex in cell cycle progression. We demonstrate that knockdown of cyclin A delayed progression through mitosis and activation of th...
Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle[J] . Vanessa Oakes,Weili Wang,Brittney Harrington,Won Jae Lee,Heather Beamish,Kee Ming Chia,Alex Pinder,Hidemasa Goto,Masaki Inagaki,Sandra Pavey,Brian Gabrielli.Cell Cycle . 2014 (20)...
CDK2/cyclin A-associated protein p45 Get Access You are viewing the full content Ubiquitin Ligase SCF-Skp2 Citations Other actions Reprints and Permissions Export citation About this Reference Work Add to Papers Share Share this content on Facebook Share this content on Twitter Share ...
<div p-id="p-0001">The present invention relates to a method of forming a crystal complex of CDK2/cyclin A and a cyclin binding groove peptide oligomer using a technique involving ligand exchange with